The hotly anticipated results are in from a landmark pair of major clinical trials of a long-acting, injectable HIV-prevention drug that only requires dosing every six months. The pharma giant has already secured approval for the injectable drug in treating highly drug-resistant HIV. Given the clear statistical superiority of lenacapavir over Truvada, the trial’s blinded phase will now be ended several months early. When taken as prescribed, Truvada is over 99% effective at preventing HIV; Descovy is comparably effective. This chorus is sure to get louder now that lenacapavir is officially highly effective at protecting gay and bisexual men and trans people as well.

---

Persons: lenacapavir, ”, Jared Baeten, “, ” Jen Kates, ” Gilead, Gilead, Truvada, ViiV Healthcare’s, Amy Killelea, Jirair Ratevosian, Hansel Tookes, ” Tookes, Dr, Boghuma, “ lenacapavir, Tim Horn Organizations: Gilead Sciences, pharma, NBC, Food and Drug Administration, Disease Control, PrEP, Yale School of Nursing, University of Miami Miller School of Medicine, NBC News, Southern, Affordable, CDC, Emory University Locations: Gilead, United States, ”, U.S, Australia, United Kingdom, Arlington , Virginia, America, South Africa, Thailand, Truvada, Atlanta, Saharan Africa